Back to top

Analyst Blog

Bayer (BAYRY - Analyst Report) inked a global agreement with Orion Corporation for the development and commercialization of ODM-201. ODM-201 is being developed for the treatment of patients suffering from prostate cancer.

Bayer and Orion intend to start a phase III program on ODM-201 later in 2014. The study will evaluate the efficacy and safety of ODM-201 in patients suffering from non-metastatic castration-resistant prostate cancer (nm-CRPC) at high risk of developing metastatic disease which can be identified because of rapid increase in Prostate Specific Antigen (PSA).

We note that Bayer will be making an upfront payment of €50 million for the agreement to Orion. Orion will also receive additional cash payments from the German company upon achieving certain development, tech transfer and commercialization milestones. Moreover, Bayer will pay tiered double-digit royalties to Orion on future global net sales of ODM-201 after approval.

As per the terms of the agreement, Bayer will be bearing the majority of costs for the future development of the candidate. ODM-201 will be commercialized globally by Bayer. However, Orion has the option to co-promote the candidate in Europe and will also be responsible for the manufacturing of the candidate.

We note that Bayer already has Nexavar, Stivarga and Xofigo in its oncology portfolio. Last week, Bayer and partner Amgen Inc. (AMGN - Analyst Report) announced that Nexavar was approved in the EU for the treatment of patients suffering from progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

Nexavar, a key oncology product at Bayer, is approved in over 100 countries around the globe. In the EU, the drug is approved for two other indications – for the treatment of patients suffering from hepatocellular carcinoma and suffering from advanced renal cell carcinoma who have had unsuccessful interferon-alpha or interleukin-2 based therapy. Bayer reported Nexavar sales of €771 million in 2013.

We are encouraged by Bayer’s progress with its oncology portfolio. However, companies like Roche (RHHBY - Analyst Report) also have a strong presence in the global market.

Bayer, a large-cap company, currently carries a Zacks Rank #4 (Sell). Some better-ranked stocks include Allergan Inc. (AGN - Analyst Report), which carries a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%